Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical needs in the field of genetic medicine. The company boasts a promising and proprietary pipeline, showcasing its commitment to harnessing cutting-edge technologies for transformative treatment solutions. With a seasoned leadership team guiding its strategic direction, Neurogene is poised to make substantial contributions to the advancement of genetic therapies, ultimately enhancing the quality of life for patients and their families impacted by these challenging conditions. As Neurogene progresses through critical clinical development phases, it stands as a key player in the evolving landscape of genetic therapeutics.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$38.60
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 10, 2026 | $-1.40 | $-1.53 | Miss -9.3% | $-1.53 | $0 | $0 | — | 1D Pre+0.3% | On-Day+2.4% | 1D Post-2.1% |
Q ended Mar 31, 2026 Reported May 12, 2026 | $-1.27 | $-1.38 | Miss -8.7% | $-1.39 | $0 | $0 | — | 1D Pre+0.4% | On-Day+2.1% | 1D Post+3.4% |
Q ended Dec 31, 2025 Reported Mar 24, 2026 | $-1.24 | $-1.13 | Beat +8.9% | |||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| $0 |
| — |
| 1D Pre+1.6% |
| On-Day+8.0% |
| 1D Post+5.4% |
Q ended Sep 30, 2025 Reported Nov 13, 2025 | $-1.09 | $-0.99 | Beat +9.2% | — | $0 | $0 | — | 1D Pre+0.7% | On-Day-14.8% | 1D Post-14.0% |